Sanofi touts 12 potential blockbusters in bid to regain investor confidence Therapeutics In an R&D event on Thursday, the French pharma is trying to win over its investors by highlighting a dozen potential blockbusters and charting strong growth for the company through 2030. Read more December 7, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/10/BioSpaceSanofi10-6-2023.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-12-07 09:45:092023-12-07 09:48:37Sanofi touts 12 potential blockbusters in bid to regain investor confidence
Novartis 2023: Prioritizing pure-play Issue Archives, October 2023, R&D, Therapeutics Following a year of transformation, Novartis is laser-focused on its goals. Read more October 10, 2023/by Maria Fontanazza https://www.pharmalive.com/wp-content/uploads/2023/10/Cosentyx-Unoready-Novartis-2023.jpg 260 650 Maria Fontanazza https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Maria Fontanazza2023-10-10 01:45:022023-10-11 08:55:15Novartis 2023: Prioritizing pure-play
